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Basic Science for Clinicians
Circulating Biomarkers of Collagen Metabolism in
Cardiac Diseases
Begon˜a Lo´pez, PhD; Arantxa Gonza´lez, PhD; Javier Díez, MD, PhD
Alterations of the structure and composition of cardio-myocyte and noncardiomyocyte compartments of the
myocardium appear to play a central role in the pathogenesis
of heart failure (HF) associated with a number of cardiac
diseases. Among these alterations, changes in the quantity
and quality of the extracellular matrix, including the collagen
network, have been characterized that induce remodeling of
the myocardium and ultimately deteriorate left ventricular
(LV) function and facilitate the development of HF. Studies
on circulating biomarkers of collagen metabolism have at-
tracted the attention of the medical community, and some
circulating biomarkers have been proposed as potential useful
tools to improve diagnosis, prognosis, and therapy in cardiac
diseases that develop HF.1 However, the available data are far
from conclusive and from affording incremental value to the
knowledge provided by more classic diagnostic tools. This is
due mainly to 3 limitations. First, collagen is the most
abundant protein in the body, and its turnover is so dynamic
that not all circulating molecules proposed as biomarkers
actually reflect changes in collagen metabolism, namely at
the cardiac level. Second, a thorough understanding of the
association of a given biomarker with the pathological fea-
tures of the collagen network in the cardiac disease under
study has not been considered essential, thus weakening its
pathophysiological meaning. Third, several methodological
issues may introduce a number of confounding factors into
the measurements of circulating biomarkers of collagen
metabolism, thus bringing into question the validity of the
available results. Therefore, this article is not aimed at
providing a systematic review of all the published informa-
tion on circulating biomarkers of collagen metabolism in
cardiac diseases but at analyzing the biochemical, pathophys-
iological, and methodological aspects to be taken into account
to overcome the above limitations and to improve the clinical
applicability of such molecules.
Circulating Biomarkers of
Collagen Metabolism
Collagen Metabolism
The extracellular matrix contains a fibrillar collagen network,
a basement membrane, proteoglycans and glycosaminogly-
cans, and bioactive signaling molecules. The collagen net-
work is a metabolically active structure in the sense that the
balance between the synthesis and degradation of collagen
determines its turnover, which is estimated to be from 80 to
120 days.2 The turnover is regulated by fibroblasts and by
fibroblasts differentiated to myofibroblasts (Figure 1).3 These
cells respond to mechanical stretch, autocrine and paracrine
factors generated locally (eg, vasoactive peptides such as
angiotensin II and growth factors such as transforming
growth factor- or connective tissue growth factor), and
hormones derived from the circulation (eg, aldosterone). In
addition, a number of proinflammatory cytokines (eg, tumor
necrosis factor-, interleukin-1 and -6) secreted by mono-
cytes and macrophages also influence the function of fibro-
blasts and myofibroblasts. The responses of these cells to all
the aforementioned factors include changes in their rates of
proliferation and migration and modifications in their capac-
ity to synthesize and secrete fibrillar collagen precursors
(namely the 2 more abundant subtypes present in the heart:
procollagen types I and III), as well as enzymes that process
procollagen precursors to mature collagen able to form fibrils
and fibers (eg, procollagen proteinases and lysyl oxidase),
enzymes that degrade collagen molecules within fibers (eg,
matrix metalloproteinases [MMPs]), and signaling molecules
that regulate the interaction of the extracellular matrix with
parenchymal cells (eg, matricellular proteins) (Figure 1). The
clinical investigation of circulating biomarkers of collagen
metabolism has provided a number of candidate molecules
that can be classified into 2 categories: biomarkers related to
the synthesis of collagen molecules that will form the new
collagen fibers and biomarkers related to the degradation of
collagen molecules integrating the old fibers.
Biomarkers Related to Collagen Synthesis
Once procollagen types I and III are synthesized and secreted
by fibroblasts and myofibroblasts as a triple-helix procolla-
gen precursor containing terminal propeptides, the propep-
tides are cleaved in block by specific procollagen proteinases,
allowing the integration of the resulting collagen molecule
into the growing fibril. The released propeptides reach the
bloodstream and can be detected in blood. If the propeptides
are cleaved in every molecule of collagen and the amount of
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propeptides quantified in the circulation is proportional to the
amount of collagen formed, these propeptides qualify as
indexes of collagen synthesis. This holds true for the carboxy-
terminal propeptide of procollagen type I (PICP) and likely
for the amino-terminal propeptide of procollagen type I
(PINP) (Figure 2).4 In fact, a stoichiometric ratio of 1:1 exists
between the number of collagen type I molecules produced
and the PICP molecules released. On the other hand, the
carboxy-terminal and amino-terminal propeptides of collagen
type III (PIIICP and PIIINP, respectively) are not completely
cleaved during the conversion of procollagen type III into
collagen type III, remaining to some extent in the final fiber
and thus also being released during fiber degradation.5
Consequently, the stoichiometric ratio between the number of
collagen type III molecules produced and the number of
PIIICP and PIIINP molecules released may vary.
Biomarkers Related to Collagen Degradation
The degradation of collagen fibers is mediated by the MMP
family of enzymes that can be inhibited by direct interaction
with naturally occurring, specific tissue inhibitors of metal-
loproteinases (TIMP-1 to TIMP-4).6 Interstitial collagenase
(MMP-1), neutrophil collagenase (MMP-8), and collage-
nase-3 (MMP-13) initiate the digestion of collagens by
hydrolyzing the peptide bond following a glycine residue
located at a distance of three quarters of the collagen
molecule length from the amino-terminal extreme. The re-
sulting one-quarter carboxy-terminal telopeptide released by
the action of MMP-1 on collagen type I (CITP) is found in an
immunochemically intact form in blood (Figure 2).7 A
stoichiometric ratio of 1:1 exists between the number of
collagen type I molecules degraded and of CITP molecules
released, and the amount of CITP that reaches the circulation
Figure 1. Schematic representation of
the different steps involved in the syn-
thesis and degradation of collagen types
I and III in the heart, as well as of the
cells and the humoral factors involved in
its regulation at the extracellular (intersti-
tium) level.
Figure 2. Peptides released during the
extracellular synthesis and degradation
of collagen type I that reach the blood-
stream from the tissue interstitium.
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is proportional to the amount of fibrillar collagen degraded.8
Therefore, CITP may qualify as an index of MMP-1–
dependent collagen type I degradation.
The resulting three-quarter fragment amino-terminal te-
lopeptide released by MMP-1 from the collagen molecule is
further degraded by MMP-2 and MMP-9 or gelatinases. The
final fragmented matrix peptides or matrikines released by
the action of these enzymes have biological activities in the
regulation of collagen metabolism and angiogenesis. For
instance, the tripeptide glycyl-histidyl-lysine (GHL) derived
from collagen type I stimulates new collagen synthesis by
fibroblasts.9 It has also been shown that GHL stimulates
MMP-2 expression and secretion by fibroblasts in culture,10
suggesting a redundant and cooperative role among some
MMPs and matrikines. Although the tripeptide GHL can be
found in human plasma (Figure 2),11 its stoichiometry relative
to the degradation of the larger collagen type I telopeptide is
unknown.
Circulating Biomarkers of Collagen
Metabolism in Cardiac Diseases
Alterations of the Myocardial Collagen Network in
Cardiac Diseases
Disturbances of collagen metabolism can lead to abnormali-
ties in the architecture and composition (ie, remodeling) of
the collagen network that, in turn, will result in alterations of
LV morphology and function (reviewed elsewhere12–14). In
some cases, increased collagen synthesis over degradation
occurs that leads to accumulation of collagen fibers. This
includes distinctive patterns of reparative and reactive myo-
cardial fibrosis, each of which alters diastolic myocardial
stiffness and facilitates ventricular hypertrophy and diastolic
dysfunction (Figure 3). Alternatively, the predominance of
degradation over synthesis leads to the disruption and loss of
myocardial collagen scaffold and/or decline in matrix tensile
strength that can be responsible for ventricular dilatation and
systolic dysfunction (Figure 3). Depending on the temporal
sequence of the disease process and on the localization, either
diffuse or focal, of the injury, these 2 patterns may coexist at
variable degrees within the same myocardium (Figure 3). It
has been proposed that the aforementioned alterations of the
collagen network are present in 4 major types of cardiac
diseases15–18: ischemic heart disease, heart disease associated
with pressure overload, heart disease associated with volume
overload, and intrinsic myocardial disease or cardiomyopathy
(Table 1).
Circulating Biomarkers of Collagen Metabolism
and Alterations of the Myocardial
Collagen Network
Because biomarkers of collagen metabolism present in blood
are not cardiac specific, the problem of how to demonstrate
their relationship with the lesions of the collagen network
present in cardiac diseases emerges. To address this issue, we
have proposed that a given circulating biomarker must be
investigated to answer a number of questions (Table 2).19
Because this is an invasive and expensive investigation, not
practical for routine assays, published information on this
topic is scarce. Nevertheless, some preliminary data are
already available that deserve to be considered.
Serum PICP
It has been observed that, in the setting of steady-state
production by extracardiac sources, PICP detected in periph-
eral blood from patients with hypertensive heart disease
Figure 3. Histological sections of endo-
myocardial biopsies from a healthy sub-
ject (A), a hypertensive patient with LV
hypertrophy showing increased intersti-
tial deposition of collagen fibers or fibro-
sis (B, arrows), a patient with ischemic
heart disease and LV dilatation showing
loss of collagen scaffold around individ-
ual cardiomyocytes and groups of car-
diomyocytes (C, arrowheads), and a
patient with idiopathic dilated cardiomy-
opathy showing both fibrosis and loss of
collagen scaffold (D, arrows and arrow-
heads). Sections were stained with
Picrosirius red; collagen is identified in
red (original magnification 20).
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(HHD) is mainly of cardiac origin because a positive gradient
exists for its serum concentration from the coronary sinus
towards antecubital vein in these patients but not in normo-
tensive subjects (Figure 420–24) and the concentrations of
peripheral and coronary PICP are highly correlated in patients
with HHD.20 PICP has been shown to be associated with
myocardial fibrosis in patients with HHD (Figure 520–23)20,21 and
patients with idiopathic dilated cardiomyopathy.25 In addition,
PICP is associated with LV mass index (Figure 5) and LV
chamber stiffness (Figure 5) in patients with HHD.20–23,26,27
Similar associations have been reported in patients with
idiopathic dilated cardiomyopathy.25 Besides, it has been
shown that PICP concentration, the extent of myocardial
fibrosis, and LV chamber stiffness change in parallel in
response to antihypertensive therapy in patients with
HHD.22,28,29 Finally, increased concentrations of PICP detect
severe fibrosis21 and predict HF with preserved ejection
fraction30 in patients with HHD with an acceptable sensitivity
and specificity.
Serum PIIINP
Although the cardiac origin of circulating PIIINP in patients
with cardiac diseases remains to be proven, an association has
been found between PIIINP concentrations and myocardial
collagen type III content in patients with ischemic heart
disease and patients with idiopathic dilated cardiomyopathy.31 In
addition, an inverse association has been found between
PIIINP and transmitral flow parameters assessing diastolic
function23 and longitudinal systolic strain assessing systolic
function32 in patients with HHD. Furthermore, increased
PIIINP shows good sensitivity and specificity for predicting
HF with preserved ejection fraction in these patients.30
Serum CITP
Whereas the pathophysiological meaning of isolated CITP
measurement still remains to be established, this peptide can
be used in combination with PICP to assess collagen type I
turnover indirectly. In fact, on the basis of data obtained in
hypertensive animals,33 it has been proposed that the circu-
lating PICP:CITP ratio may be an index of the degree of
coupling between the synthesis and the degradation of colla-
gen type I. Of interest, the ratio is associated with the severity
of myocardial fibrosis in patients with HHD,22 suggesting that
an increased ratio, reflecting the predominance of synthesis
over degradation, may lead to fibrosis in these patients.
Plasma MMP-1
A higher concentration of MMP-1 has been found in coronary
sinus blood compared with antecubital vein blood in patients
with HHD but not in normotensive subjects (Figure 4).24
Moreover, a highly significant direct correlation has been
found between MMP-1 detected in coronary blood and
peripheral blood in these patients.24 Of interest, in patients
with HHD and HF, MMP-1 concentration measured in
peripheral blood increases in parallel with the increase in
Table 2. Questions to Be Answered Before a Circulating
Molecule Can Be Considered as a Biomarker of the Myocardial
Collagen Network
Is there an association between its expression or mechanism of production
in the myocardium and its blood concentration?
Is there a positive gradient from its concentration in coronary sinus blood
toward its concentration in peripheral vein blood, thus proving its main
cardiac origin?
Are there associations of its concentration in blood with the myocardial
histopathological alteration and the disturbances of LV morphology and
function under study?
Do its levels vary in parallel with the changes in the above myocardial
alteration and LV disturbances induced by treatment?
Does it exhibit adequate diagnostic performance (eg, sensitivity and
specificity) to detect the histopathological alterations under study?
Table 1. Alterations of the Collagen Matrix Present in Cardiac Diseases
Cardiac Diseases Myocardial Fibrosis
Loss of Myocardial Collagen
Scaffold
Ischemic heart disease
With previous MI Develops late within the infarct zone and
may appear remote to the infarct zone
Appears early within the infarct
zone
Without previous MI Parallels the development of HF
Pressure overload
HHD Accompanies the development of cLVH
and diastolic dysfunction
Is associated with the deterioration
of systolic function
Aortic stenosis Accompanies the development of cLVH
Volume overload
Mitral regurgitation Accompanies the development of
eLVH
Cardiomyopathy
Idiopathic dilated cardiomyopathy Parallels the development of HF
Diabetic cardiomyopathy Accompanies the development of LVH
and LV dysfunction
Hypertrophic cardiomyopathy Accompanies the development of LVH
and LV dysfunction
MI indicates myocardial infarction; HHD, hypertensive heart disease; cLVH, concentric LV hypertrophy; and eLVH, eccentric LV
hypertrophy.
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myocardial MMP-1 expression and is higher in patients with
loss of myocardial collagen scaffold than in patients without
this lesion (Figure 6).24 In addition, MMP-1 is directly
associated with LV end-diastolic volume dimensions (Figure
6) and inversely with ejection fraction (Figure 6) in patients
with HHD and HF.24 Thus, in the setting of steady-state
production by extracardiac sources, an excess of circulating
MMP-1 in patients with HHD can be considered of cardiac
origin. Whereas myocardial MMP-1 expression has been
reported to be altered in patients with cardiac diseases
associated with either fibrosis (eg, aortic stenosis34) or loss of
collagen scaffold (eg, idiopathic dilated cardiomyopathy35
and ischemic heart disease36), no studies have been performed
to analyze the association of myocardial and circulating
MMP-1 in these patients.
Plasma TIMP-1
A positive gradient and a direct correlation have been
reported between TIMP-1 concentration in coronary sinus
blood and TIMP-1 concentration in antecubital vein blood in
patients with HHD after exclusion of other extracardiac
sources, suggesting the potential cardiac origin of circulating
TIMP-1 in these patients.24 However, the association of the
circulating levels of this molecule with its myocardial expres-
sion has not yet been demonstrated. Increased TIMP-1 has
been found to exhibit good sensitivity and specificity for
predicting diastolic dysfunction37 and HF with preserved
ejection fraction38 in patients with HHD. Interestingly, it has
been reported that TIMP-1 is an independent predictor of
all-cause mortality risk in patients with chronic HF and that
its prognostic information is incremental when added to a set
of clinical and biochemical chronic HF descriptors.39
On the other hand, it has been proposed that the circulating
MMP-1:TIMP-1 ratio may serve as an indirect index of
circulating unbound MMP-1. In this regard, an abnormally
low MMP-1:TIMP-1 ratio has been found in patients with
hypertrophic cardiomyopathy and passive diastolic dysfunc-
tion.40 It has been reported that the circulating MMP-
1:TIMP-1 ratio is directly associated with LV end-diastolic
diameter and inversely associated with ejection fraction in
patients with HHD.24 Of interest, an association has been
reported between the MMP-1:TIMP-1 ratio and the degrada-
tion of collagen fibers in patients with idiopathic dilated
cardiomyopathy before and after LV assist device support.41
Other Circulating Biomarkers
Whereas parallel changes in myocardial collagen content and
serum PINP have been reported in HF patients presenting
reverse LV geometric remodeling after prolonged LV assist
device support,42 no significant correlations were found
between the 2 parameters. On the other hand, although
plasma MMP-9 levels have been found to be associated with
Figure 4. Serum concentration of PICP
(A) and plasma MMP-1 (B) measured in
blood from the coronary sinus and blood
from the antecubital vein in normoten-
sive control subjects (white columns)
and hypertensive patients with HF (solid
columns). *P0.01 vs control subjects.
Data derived from References 20
through 24.
Figure 5. Associations found between
serum concentration of PICP measured
in blood from the antecubital vein and
histologically assessed collagen volume
fraction divided in tertiles (A), LV mass
index (B), and LV chamber stiffness (C)
in hypertensive patients. Data derived
from References 20 through 23.
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late gadolinium enhancement by cardiac magnetic resonance
(a potential index of myocardial collagen content) in patients
with hypertrophic cardiomyopathy,43 no data are available in
the literature on the association of circulating gelatinases with
alterations of the myocardial collagen network in cardiac
patients. Finally, there is no available information on serum
PIIICP in cardiac diseases.
Aspects Influencing the Clinical Evaluation
of Circulating Biomarkers of
Collagen Metabolism
Aspects Related to the Immunoassay Method
of Detection
All the aforementioned peptides and proteins can be mea-
sured in serum or plasma samples easily, reproducibly, and
inexpensively with commercially available ELISAs or radio-
immunoassays. However, different commercial kits for the
same biomarker may give variable quantitative results, de-
pending on the antibodies and standards used; therefore, it is
important to standardize these determinations before applying
them to routine clinical practice. More important, this aspect
must be taken into account in comparisons of values of 1
biomarker provided by different studies using different methods.
On the other hand, whereas most of the peptides generated
during the processing of procollagen types I and III are found
as 1 antigen form in serum, PINP appears in 2 different
forms: 1 form corresponding to the whole propeptide and a
smaller form that is the product of its degradation.44 It is thus
important to use assays that can identify the intact molecule
as the biomarker of interest.
Aspects Related to the Elimination of Circulating
Biomarkers From the Circulation
Another potential confounding factor in the interpretation of
blood concentrations of collagen markers is their pathway of
elimination. The propeptides PICP and PIIINP are cleared via
uptake by endothelial cells in the liver.45,46 As a consequence,
in conditions of chronic liver insufficiency, the increases in
their serum concentrations may reflect reduced hepatic clear-
ance but not increased production. On the other hand, CITP is
believed to be cleared through the kidneys because of its
small size (12 kDa). Thus, a glomerular filtration rate2 50
mL  min1  1.73 m1 facilitates the increase in CITP serum
concentration.7
The mechanisms for the clearance of MMPs and TIMPs
are not yet fully understood. One mechanism for MMPs may
be their own autoproteolysis, as shown for MMP-1.47 Extra-
cellular MMP concentrations can also be regulated by direct
clearance of the intact proteins via low-density lipoprotein–
related scavenger receptors and subsequent degradation.48 In
addition, cleavage of 2-macroglobulin by most MMPs in-
duces a conformational change that irreversibly traps the
enzyme.49 This complex is eventually endocytosed and de-
graded. Of interest, MMP-1 bound to 2-macroglobulin is not
recognized by most of the kits for the detection of circulating
MMP-1.
Aspects Related to the Demographics of
the Subjects
It is important to note that the serum concentrations of some
of the above biomarkers may change as a function of
demographics in the absence of cardiovascular disease. For
instance, in infants and children, serum PICP concentration
correlates with growth velocity50; thus, it is physiologically
increased in these populations. On the other hand, in
community-based studies, it has been reported that PIIINP
levels increased with age and body mass index51 and that
TIMP-1 levels increased with age and male sex.52 Thus, the
confounding influence of these factors must be excluded in
all studies of circulating biomarkers of collagen metabolism.
Aspects Related to the Presence of Comorbidities
Taking into account the diversity of tissue sources of collagen
biomarkers considered here, changes in their blood levels
Figure 6. MMP-1 measured in blood
from the antecubital vein in hypertensive
patients with HF classified in accordance
with the absence or presence of
endomysial collagen disruption (A), and
associations of MMP-1 with LV end-
diastolic volume (B) and LV ejection frac-
tion (C) in hypertensive patients with HF.
Data derived from Reference 24.
Reprinted from Lo´pez et al,24 Copyright
© 2006, with permission from Elsevier.
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may be related not to alterations of the myocardial collagen
network but to alterations of collagen in other organs. Some
preliminary data suggest that changes in concentrations of
some of these biomarkers present in patients with vascular
diseases represent integrated abnormalities of the cardiovas-
cular collagen. For instance, it has been reported that arterial
stiffness was directly correlated with serum PICP in elderly
patients with HHD.53 Other authors have reported an inverse
association between arterial stiffness and plasma MMP-1 in
hypertensive patients.54 Although no cardiac parameters were
included in a multiple regression analysis to assess whether
they influenced the correlations between arterial stiffness and
serum biomarkers, these observations suggest that in arterial
hypertension, alterations in these molecules may reflect
disturbances of collagen metabolism that occur not just at the
myocardial but also at the arterial wall level.
On the other hand, the presence of concomitant noncardio-
vascular diseases affecting collagen matrix can also affect the
circulating levels of these molecules because none of them
are exclusively from a cardiac origin (Table 355–60). This
means that before changes in blood concentrations of biomar-
kers of collagen metabolism can be specifically attributed to
alterations in myocardial collagen network, the presence of
these conditions must be excluded in the patients under study.
Aspects Related to the Effects of
Pharmacological Treatment
Finally, it is of note that long-term pharmacological treat-
ment, namely with drugs used to treat cardiovascular dis-
eases, may modify the serum levels of biomarkers of collagen
metabolism. For instance, it has been reported that serum
PICP decreases in hypertensive patients being treated with
angiotensin type 1 receptor antagonists28,61–64 or HF patients
treated with the loop diuretic torasemide,27,29 PIIINP de-
creases in HF patients treated with aldosterone antago-
nists,65–68 CITP and MMP-1 increase in hypertensive patients
treated with angiotensin-converting enzyme inhibitors,69,70
and CITP decreases in hypercholesterolemic patients treated
with statins.71 Thus, the potential influence of previous
pharmacological treatment must be carefully considered in
studies assessing serum biomarkers of collagen metabolism
in cardiac patients.
Aspects Related to the Cost-Benefit Analysis
Imaging technologies can assess cardiac diseases in humans
with a higher degree of sensitivity and specificity than
biochemical methods. Magnetic resonance imaging is a
promising technique, with the late gadolinium enhancement
areas in the myocardium probably representing fibrotic re-
gions.72 This methodology is also rapidly evolving to involve
imaging and monitoring of collagen synthesis (ie, using
99mTc-labeled peptides that bind to activated fibroblasts).73
The negative aspects of these methodologies compared with
the immunoassays of circulating biomarkers are the high cost,
technical difficulty, and low availability. Indeed, the eco-
nomic impact of biochemical and/or imaging technologies is
a major issue for national health systems and the necessity to
make present-day advanced technology cost-effective. How-
ever, the anticipated resultant reduction in morbidity and
mortality with longer productive lives may tremendously
offset those costs.
From all the above considerations, it is obvious that the
influence of a number of methodological limitations and
potential confounding factors need to be carefully taken into
account when measuring and interpreting circulating biomar-
kers of collagen metabolism in patients with cardiac diseases.
Therefore, although numerous articles have been published
reporting alterations of these biomarkers in cardiac diseases
that are associated with either myocardial fibrosis or loss of
myocardial collagen scaffold, just a few meet this require-
Table 4. Alterations of Circulating Biomarkers of Collagen Metabolism in Patients With Cardiac Diseases Associated
With Lesions of the Collagen Network
Cardiac Diseases PICP PICP:CITP PIIINP MMP-1 MMP-1:TIMP-1
Ischemic heart disease 74–77 78 31, 65–68, 76,79–82 83–87
Hypertensive heart disease 20, 21, 28–30, 61, 62, 88 22, 28 23, 32, 88–90 24 24
Aortic stenosis 91
Mitral regurgitation
Idiopathic dilated cardiomyopathy 25 31 92 93
Diabetic cardiomyopathy 63, 94
Hypertrophic cardiomyopathy 40, 64 95
 Indicates abnormally increased level or ratio. Numbers are references.
Table 3. Alterations of Circulating Collagen-Derived Peptides
in Patients With Noncardiac Diseases
Diseases
Major Alterations of
Serum Biomarkers Reference
Metastatic bone disease (cancer of
the breast, lung, prostate, and other sites)
CITP 55
Metabolic bone disease (severe
osteoporosis)
PICP, PINP 56
Chronic liver diseases (cirrhosis of
different origins)
PIIINP 57
Chronic kidney disease (stages 4
and 5 with high-turnover
bone disease)
PICP, CITP 58
Other inflammatory and fibrogenic
diseases
Osteoarthritis, rheumatoid arthritis PIIINP, CITP 59
Diffuse fibrosing lung disease PICP, CITP 60
 Indicates abnormally increased level or ratio.
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ment and thus provide information on potential clinical
usefulness (Table 420–25,28–31,40,61–68,74–95). Of interest, some
of these studies report alterations in 1 biomarker, thus
providing the opportunity for a several-biomarker combina-
tion as a more informative approach to the alterations of
collagen metabolism under study.
Conclusions and Future Directions
Despite the available information on circulating biomarkers
of collagen metabolism, a number of major limitations remain
that weaken their clinical usefulness. It is likely that these
limitations are the result of the lack of adequate strategies to
investigate a given biomarker from its pathobiological fun-
damentals to its assessment in clinical practice. Therefore, the
time has come for collaborative research initiatives aimed at
definitively covering in an integrated manner the following
aspects: (1) demonstration of the connections between the
measured levels of the molecules proposed as biomarkers, the
lesions of the myocardial collagen network, and the alter-
ations of LV anatomy and function; (2) prospective validation
of incremental information provided by a multimarker strat-
egy combining these molecules with standard biochemical
markers (eg, circulating natriuretic peptides) and emerging
genetic and imaging markers in independent populations; (3)
assessment of effects of their measurements on patient
management and outcomes; and (4) evaluation of the feasi-
bility and cost-effectiveness of the application of this strategy
in the community. With the information provided in this
review, some biomarkers emerge as the most appropriate
candidates for initiating such a collaborative research.
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